Diabetes
Year in review: Seven updates on ultraprocessed foods
This year, Healio covered major developments in research on ultraprocessed foods, which continue to have a significant and polarizing presence in nutrition and health.
Dulaglutide reduces risk for weight gain among women who quit smoking
Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to researchers.
Top in endocrinology: Updates in obesity treatment
Adults with obesity can achieve 15% or more weight loss with nutrient-stimulated, hormone-based therapies, but treating obesity involves more than just reducing a person’s body weight, an expert said.
Patients with diabetes at higher risk for acute renal failure after hip replacement
SAN DIEGO — Patients with diabetes mellitus who undergo total hip arthroplasty demonstrate an increased risk for health care use, including increased length of stay, and acute renal failure, according to a speaker at ACR Convergence 2023.
Patients with pregnancy-related ESKD may have reduced transplant access, face racial gaps
Adults with pregnancy-related end-stage kidney disease have reduced access to transplant and nephrology care, which may worsen racial gaps for Black patients with this condition, according to a study.
Top in endocrinology: Incretin-based therapies; updated diabetes guidance
Incretin-based therapies, which were developed for the treatment of diabetes and obesity because of their ability to target defects that are not addressed by other medications, are continuing to evolve.
Empagliflozin may reduce ventricular arrhythmias in patients with type 2 diabetes, ICDs
PHILADELPHIA — In the EMPA-ICD trial, patients with type 2 diabetes and an implantable cardioverter defibrillator had fewer ventricular arrhythmias at 24 weeks when assigned empagliflozin compared with placebo.
AGA opposes holding GLP-1 agonists for endoscopy without ‘high-level published evidence’
Updated AGA clinical practice guidelines reiterated the society’s stance that there is little data to support the recommendation that all patients should stop glucagon-like peptide-1 receptor agonists prior to elective endoscopy procedures.
Use of finenerone to reduce albuminuria improves kidney, cardiovascular outcomes
The use of finenerone to reduce albuminuria in patients with chronic kidney disease and type 2 diabetes provided kidney and cardiovascular benefits when the urine albumin-to-creatine ratio was reduced by 30% or more, a study shows.
About 40% of patients with type 2 diabetes discontinue second-line medication
Almost 40% of patients with type 2 diabetes stopped taking their second-line medication within 1 year, putting them at risk for future hospitalization related to diabetes, according to researchers.